title: Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke.
abstract: OBJECTIVE
  The purpose of this study was to examine the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients with acute ischemic stroke.
  
  
  BACKGROUND
  The rapid and reliable estimation of prognosis in acute ischemic stroke is pivotal to optimize clinical care. MR-proANP, a recently described, stable fragment of the ANP precursor hormone, may be useful in this setting.
  
  
  METHODS
  In a prospective observational study, we measured MR-proANP on admission in plasma of 362 consecutive patients presenting with acute ischemic stroke. The prognostic value of MR-proANP to predict mortality within 90 days and functional outcome (defined as a modified Rankin Scale of ≤2 or ≥3) was evaluated and compared with the National Institutes of Health Stroke Scale (NIHSS) score.
  
  
  RESULTS
  The discriminatory accuracy, calculated with the area under the curve (AUC) of the receiver operating characteristics curve, of MR-proANP to predict death was comparable to the NIHSS (AUC: 0.86 [95% confidence interval (CI): 0.82 to 0.90] and 0.85 [95% CI: 0.81 to 0.89; p = 0.7]). Combined, the accuracy significantly improved (0.92 [95% CI: 0.88 to 0.96; p < 0.01]). The AUC of MR-proANP to predict functional outcome was 0.70 (95% CI: 0.65 to 0.75), similar to the NIHSS (0.75 [95% CI: 0.70 to 0.80]; p = 0.16). The prognostic value of MR-proANP for both outcomes was independent of the NIHSS. Higher MR-proANP concentrations were found in stroke of cardioembolic etiology.
  
  
  CONCLUSIONS
  MR-proANP is a prognostic marker in the acute phase of stroke, improving the discriminatory value of the NIHSS, independently predicting post-stroke mortality and functional outcome. (The "COSMOS"-Study [Copeptin in Osmoregulation and Stress Assessment]; NCT00390962).
authors.affiliation: Department of Endocrinology, University Hospital Basel, Basel, Switzerland. katanm@uhbs.ch
authors.forename: Mira
authors.initials: M
authors.lastname: Katan
authors.forename: Felix
authors.initials: F
authors.lastname: Fluri
authors.forename: Philipp
authors.initials: P
authors.lastname: Schuetz
authors.forename: Nils G
authors.initials: NG
authors.lastname: Morgenthaler
authors.forename: Christian
authors.initials: C
authors.lastname: Zweifel
authors.forename: Roland
authors.initials: R
authors.lastname: Bingisser
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kappos
authors.forename: Andreas
authors.initials: A
authors.lastname: Steck
authors.forename: Stefan T
authors.initials: ST
authors.lastname: Engelter
authors.forename: Beat
authors.initials: B
authors.lastname: Müller
authors.forename: Mirjam
authors.initials: M
authors.lastname: Christ-Crain
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D009320:Atrial Natriuretic Factor / Q000097:blood*; D015415:Biomarkers; D002545:Brain Ischemia; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D020521:Stroke / Q000097:blood*
chemical_list: D015415:Biomarkers; C552580:midregional pro-atrial natriuretic peptide, human; D009320:Atrial Natriuretic Factor